158 related articles for article (PubMed ID: 23597945)
1. Tumor hypoxia and metabolism -- towards novel anticancer approaches.
Chiche J; Ricci JE; Pouysségur J
Ann Endocrinol (Paris); 2013 May; 74(2):111-4. PubMed ID: 23597945
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.
Chiche J; Ilc K; Laferrière J; Trottier E; Dayan F; Mazure NM; Brahimi-Horn MC; Pouysségur J
Cancer Res; 2009 Jan; 69(1):358-68. PubMed ID: 19118021
[TBL] [Abstract][Full Text] [Related]
3. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin.
Marchiq I; Le Floch R; Roux D; Simon MP; Pouyssegur J
Cancer Res; 2015 Jan; 75(1):171-80. PubMed ID: 25403912
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters.
Marchiq I; Pouysségur J
J Mol Med (Berl); 2016 Feb; 94(2):155-71. PubMed ID: 26099350
[TBL] [Abstract][Full Text] [Related]
5. Regulation of glyceraldehyde-3-phosphate dehydrogenase by hypoxia inducible factor 1 in the white shrimp Litopenaeus vannamei during hypoxia and reoxygenation.
Camacho-Jiménez L; Leyva-Carrillo L; Peregrino-Uriarte AB; Duarte-Gutiérrez JL; Tresguerres M; Yepiz-Plascencia G
Comp Biochem Physiol A Mol Integr Physiol; 2019 Sep; 235():56-65. PubMed ID: 31100464
[TBL] [Abstract][Full Text] [Related]
6. Knock out of the BASIGIN/CD147 chaperone of lactate/H+ symporters disproves its pro-tumour action via extracellular matrix metalloproteases (MMPs) induction.
Marchiq I; Albrengues J; Granja S; Gaggioli C; Pouysségur J; Simon MP
Oncotarget; 2015 Sep; 6(28):24636-48. PubMed ID: 26284589
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia: A Double-Edged Sword in Cancer Therapy.
Manoochehri Khoshinani H; Afshar S; Najafi R
Cancer Invest; 2016 Nov; 34(10):536-545. PubMed ID: 27824512
[TBL] [Abstract][Full Text] [Related]
8. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
Kim Y; Choi JW; Lee JH; Kim YS
Hum Pathol; 2015 Jan; 46(1):104-12. PubMed ID: 25456395
[TBL] [Abstract][Full Text] [Related]
9. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance.
Kilic M; Kasperczyk H; Fulda S; Debatin KM
Oncogene; 2007 Mar; 26(14):2027-38. PubMed ID: 17043658
[TBL] [Abstract][Full Text] [Related]
10. Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
Patiar S; Harris AL
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560
[TBL] [Abstract][Full Text] [Related]
11. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase.
Kaluz S; Kaluzová M; Chrastina A; Olive PL; Pastoreková S; Pastorek J; Lerman MI; Stanbridge EJ
Cancer Res; 2002 Aug; 62(15):4469-77. PubMed ID: 12154057
[TBL] [Abstract][Full Text] [Related]
12. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
[TBL] [Abstract][Full Text] [Related]
13. The HIF pathway in cancer.
Maxwell PH
Semin Cell Dev Biol; 2005; 16(4-5):523-30. PubMed ID: 16144689
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Xia Y; Choi HK; Lee K
Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.
Burroughs SK; Kaluz S; Wang D; Wang K; Van Meir EG; Wang B
Future Med Chem; 2013 Apr; 5(5):553-72. PubMed ID: 23573973
[TBL] [Abstract][Full Text] [Related]
16. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.
Brahimi-Horn C; Pouysségur J
Bull Cancer; 2006 Aug; 93(8):E73-80. PubMed ID: 16935775
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors.
Yasuda Y; Arakawa T; Nawata Y; Shimada S; Oishi S; Fujii N; Nishimura S; Hattori A; Kakeya H
Bioorg Med Chem; 2015 Apr; 23(8):1776-87. PubMed ID: 25773014
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
Thiry A; Dogné JM; Masereel B; Supuran CT
Trends Pharmacol Sci; 2006 Nov; 27(11):566-73. PubMed ID: 16996620
[TBL] [Abstract][Full Text] [Related]
19. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc.
Koshiji M; Kageyama Y; Pete EA; Horikawa I; Barrett JC; Huang LE
EMBO J; 2004 May; 23(9):1949-56. PubMed ID: 15071503
[TBL] [Abstract][Full Text] [Related]
20. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.
Ganapathy-Kanniappan S; Kunjithapatham R; Geschwind JF
Anticancer Res; 2013 Jan; 33(1):13-20. PubMed ID: 23267123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
